{
  "id": "6278da4456bf9aee6f00000f",
  "type": "yesno",
  "question": "Is thalidomide used as an immunomodulatory drug nowadays?",
  "ideal_answer": "Yes.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29920472",
    "http://www.ncbi.nlm.nih.gov/pubmed/11734114",
    "http://www.ncbi.nlm.nih.gov/pubmed/17168659",
    "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
    "http://www.ncbi.nlm.nih.gov/pubmed/1605898",
    "http://www.ncbi.nlm.nih.gov/pubmed/28154372",
    "http://www.ncbi.nlm.nih.gov/pubmed/17369076",
    "http://www.ncbi.nlm.nih.gov/pubmed/28571559",
    "http://www.ncbi.nlm.nih.gov/pubmed/12803319",
    "http://www.ncbi.nlm.nih.gov/pubmed/20223727",
    "http://www.ncbi.nlm.nih.gov/pubmed/16305990",
    "http://www.ncbi.nlm.nih.gov/pubmed/20617746",
    "http://www.ncbi.nlm.nih.gov/pubmed/15327481",
    "http://www.ncbi.nlm.nih.gov/pubmed/29285050",
    "http://www.ncbi.nlm.nih.gov/pubmed/12789488",
    "http://www.ncbi.nlm.nih.gov/pubmed/22233815",
    "http://www.ncbi.nlm.nih.gov/pubmed/21048383",
    "http://www.ncbi.nlm.nih.gov/pubmed/15709921",
    "http://www.ncbi.nlm.nih.gov/pubmed/15718159",
    "http://www.ncbi.nlm.nih.gov/pubmed/12412207",
    "http://www.ncbi.nlm.nih.gov/pubmed/12190008"
  ],
  "snippets": [
    {
      "text": "Potential immunomodulatory, antiinflammatory, anti-angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic and immunomodulatory activities, and its therapeutic effect on myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide is an immunomodulatory agent; although its mechanisms of action are not fully understood, many authors have described its anti-inflammatory and immunosuppressive properties",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12412207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15709921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs (IMiDs)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16305990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15709921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide is a drug that, since its development, has made history in the world of medicine--having been withdrawn and now has returned with a boom as an anticancer and immunomodulatory drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno-modulatory drug.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21048383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11734114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Only in the last several years has thalidomide been aggressively investigated for its antiangiogenic potential and immunomodulatory properties in various tumor types.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11734114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs (IMiDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16305990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the present review an attempt is made to highlight the immunomodulatory action of thalidomide in various pathologic conditions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide and its immunomodulatory analogues have numerous effects on the body's immune system, including potential anti-cancer and anti-inflammatory activities.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15718159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide is an immunomodulatory agent; although its mechanisms of action are not fully understood, many authors have described its anti-inflammatory and immunosuppressive properties.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12412207",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide (Thal) has antiangiogenic and immunomodulatory activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17168659",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases;",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28154372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The immunomodulatory agents thalidomide and lenalidomide and the proteasome inhibitor bortezomib are now routine components of MM therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20223727",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although thalidomide was withdrawn in the 1960s after its teratogenic property was recognized, it was subsequently found that this drug possesses immunomodulatory and anti-inflammatory effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15327481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Its immunological effects were known already from earlier studies. Nowadays its use is accepted in myeloma therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20617746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therapeutics that have proven to be highly effective include the immunomodulatory drug thalidomide and its newer analogs, lenalidomide and pomalidomide, as well as the proteasome inhibitors bortezomib and carfilzomib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29920472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29285050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12803319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide has various immunomodulatory effects. Thalidomide inhibits TNF alpha production, has T-cell costimulatory properties and modulates the expression of cell surface molecules on leukocytes in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12190008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " thalidomide has been a target of active investigation in both malignant and inflammatory conditions. Although initially developed for its sedative properties, decades of investigation have identified a multitude of biological effects that led to its classification as an immunomodulatory drug (IMiD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17369076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12789488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This effect is probably due to a direct influence on the immune system",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1605898",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}